Chuangyebang was informed that recently, Shanghai Thermo Biotechnology Co., Ltd. received 150 million yuan in C1 round of financing and tens of millions of yuan in bank loans. This round of financing was jointly invested by Guanzi Venture Capital, Tianrui Fengnian and Yixing Huarui. The financing funds are planned to be used to accelerate clinical trials and international collaborations of multiple projects in the company’s R&D pipeline, as well as preclinical development of follow-up projects.
ThermoBio was established in 2014. It is an innovation-oriented global innovative biotechnology company with the mission of relieving and relieving the pain of the majority of patients and improving the quality of life. It is committed to targeting pain, inflammation and central nervous system related diseases. of new drug development. The company is headquartered in Shanghai, China, and has branches in Guangdong, Jiangsu, Australia, and the United States. It has established the first complete drug innovation and transformation platform in China, and has applied for nearly 100 domestic and foreign patents for core products. Intellectual Property and Global Market Rights.
At present, ThermoBio has built 8 international innovative drug pipelines, and 3 products including SR419, SR750, and SR1375 have become drug candidates for multi-center clinical research in China, the United States and Australia. Among them, the company’s self-developed candidate drug SR419 with a new mechanism of action for the treatment of peripheral neuropathic pain has received IND approval from the U.S. Food and Drug Administration (FDA) and was granted Fast Track qualification by the U.S. FDA in May 2022 (Fast Track Designation, FTD), a number of international multi-center clinical phase II trials evaluating SR419 and SR750 are underway. Recently, the international multi-center phase II clinical study of SR1375, a neuroinflammation treatment candidate drug independently developed by the company with a new mechanism of action, has also been approved by the US FDA.
Chen Bin, general manager of Guanzi Ventures, said that the neuropathic pain and mixed pain track where ThermoBio is located has a global market size of tens of billions of dollars, and the existing first-line drugs have many deficiencies. Provide a full range of solutions. ThermoBio’s more than 20 years of accumulation in the field of pain have achieved its global breakthrough in the field of pain, and it also maintains a global leadership in the field of neuroinflammation. With strong differentiation advantages and rapid clinical advancement, we are firmly optimistic about the future application and market value of the company’s products in the field of pain and inflammation.
Zhou Xiaojiao, a partner of Tianrui Fengnian, said: Congratulations to the company for completing a new round of large financing. At present, the overall investment in the biopharmaceutical industry is cold, and only truly high-quality assets will pass through the cycle and gain continuous recognition. ThermoBio focuses on the areas of pain and inflammation with high barriers to drug research and development, and adheres to the original target discovery and high-success rate medical transformation research and development model. The company’s core products have entered clinical phase II and are scarce assets in the world. We believe that ThermoBio can go through trials and cycles, forging ahead and bucking the trend on the road to the birth of innovative new drugs.
Dr. Li Shuai, founder and CEO of ThermoBio, said: Since its establishment 8 years ago, the company has gone through a complete path from scientific basic theoretical research, translational medicine to clinical phase II verification, and has built an internationally competitive pain and inflammation clinic. The product pipeline has reserved a variety of CNS products with market potential. We are very grateful to the new and old investment institutions for their recognition and support of the company, which has provided a strong boost for the company’s future growth. As a local innovative pharmaceutical company in China, ThermoBio has always shouldered a great sense of mission to promote Chinese local innovative drugs to the world. In the future, we will continue to deepen industrial research to benefit Chinese and even global patients with safer and more effective drugs.
media coverage
Investment Community Venture Bangtou China Network
This article is reprinted from: https://readhub.cn/topic/8kLIeENlwIz
This site is for inclusion only, and the copyright belongs to the original author.